Multiple Sclerosis - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Multiple Sclerosis - Pipeline Review, H1 2018’, provides an overview of the Multiple Sclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis

The report reviews pipeline therapeutics for Multiple Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Multiple Sclerosis therapeutics and enlists all their major and minor projects

The report assesses Multiple Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Multiple Sclerosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma PLC

AB Science SA

AbbVie Inc

Abion Inc

Abzena Plc

Acorda Therapeutics Inc

Actelion Pharmaceuticals Ltd

Addex Therapeutics Ltd

Adhaere Pharmaceuticals Inc

Aegis ...

4D Pharma PLC

AB Science SA

AbbVie Inc

Abion Inc

Abzena Plc

Acorda Therapeutics Inc

Actelion Pharmaceuticals Ltd

Addex Therapeutics Ltd

Adhaere Pharmaceuticals Inc

Aegis Therapeutics LLC

Affectis Pharmaceuticals AG

AiCuris GmbH & Co KG

Alpha Cancer Technologies Inc

Amarna Therapeutics BV

Anavex Life Sciences Corp

Antisense Therapeutics Ltd

Antoxis Ltd

Aphios Corp

Apitope International NV

Arven Ilac

AstraZeneca Plc

Atara Biotherapeutics Inc

Athersys Inc

Atlantic Bio Sci LLC

Axxam SpA

Baliopharm AG

BioApex sro

Biocad

Biocon Ltd

Biogen Inc

BioHealthonomics Inc

Biond Biologics Ltd

Bionovis SA

Bionure Farma SL

Biovista Inc

Bolder Biotechnology Inc

Boston Pharmaceuticals Inc

BrainStorm Cell Therapeutics Inc

Bristol-Myers Squibb Co

BTB Pharma AB

CASI Pharmaceuticals Inc

Celgene Corp

Cell2B Advanced Therapeutics SA

Cellix Bio Pvt Ltd

Cinnagen Co

Cognosci Inc

Coherus BioSciences Inc

Commence Bio Inc

Complement Pharma BV

Compugen Ltd

Cotinga Pharmaceuticals Inc

CuraVac Inc

Cyxone AB

DanDrit Biotech A/S

Denceptor Therapeutics Ltd

Domain Therapeutics SA

Eli Lilly and Co

Endece LLC

Evgen Pharma Plc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

FPRT Bio Inc

Gemac SA

Genervon Biopharmaceuticals LLC

GeNeuro SA

Gilead Sciences Inc

GlaxoSmithKline Plc

Glialogix Inc

Gliknik Inc

GlyTag LLC

Hansa Medical AB

Harbor Therapeutics Inc

Humanigen Inc

ImCyse SA

Immune Response BioPharma Inc

Immungenetics AG

Immunwork Inc

Inception Sciences Inc

Io Therapeutics Inc

Istesso Ltd

Johnson & Johnson

Jyant Technologies Inc

Kadimastem Ltd

Kadmon Corp LLC

KAHR medical Ltd

Karo Pharma AB

Kyorin Pharmaceutical Co Ltd

Lead Discovery Center GmbH

LFB SA

Lipocure Ltd

Longevity Biotech Inc

M3 Biotechnology Inc

Mapi Pharma Ltd

Maruho Co Ltd

MedAnnex Ltd

MedDay SA

Merck KGaA

Meta-IQ ApS

Mitochon Pharmaceuticals Inc

Mitotech SA

Mitsubishi Tanabe Pharma Corp

Mochida Pharmaceutical Co Ltd

Momenta Pharmaceuticals Inc

MorphoSys AG

Mount Tam Biotechnologies Inc

Neuren Pharmaceuticals Ltd

Neurofx Inc

Neuronax SAS

New World Laboratories Inc

Novartis AG

Nuevolution AB

Numab Innovation AG

Ogeda SA

Omeros Corp

OncoImmune Inc

Oryzon Genomics SA

OSE Immunotherapeutics

Pangen Biotech Inc.

Parvus Therapeutics Inc

Pfizer Inc

Principia Biopharma Inc

ProNoxis AB

Quimatryx SL

ReceptoPharm Inc

RedHill Biopharma Ltd

RegeneRx Biopharmaceuticals Inc

Renovo Neural Inc

Resverlogix Corp

ReveraGen BioPharma Inc

Rewind Therapeutics NV

Rhizen Pharmaceuticals SA

Rigel Pharmaceuticals Inc

Rodos BioTarget GmbH

Rubius Therapeutics Inc

SanBio Inc

Sanofi

Sareum Holdings Plc

Senju Pharmaceutical Co Ltd

Sorrento Therapeutics Inc

Synthon Holdings BV

Teikoku Pharma USA Inc

Tetra Discovery Partners LLC

Teva Pharmaceutical Industries Ltd

Tiziana Life Sciences Plc

Toleranzia AB

TolerogenixX GmbH

Topas Therapeutics GmbH

TxCell SA

Vaccinex Inc

Vakzine Projekt Management GmbH

Vicore Pharma AB

Vitality Biopharma Inc

Yeda Research and Development Company Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 10

Multiple Sclerosis – Overview 11

Multiple Sclerosis – Therapeutics Development 12

Multiple Sclerosis – Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 10

Multiple Sclerosis – Overview 11

Multiple Sclerosis – Therapeutics Development 12

Multiple Sclerosis – Therapeutics Assessment 48

Multiple Sclerosis – Companies Involved in Therapeutics Development 70

Multiple Sclerosis – Drug Profiles 135

Multiple Sclerosis – Discontinued Products 743

Multiple Sclerosis – Product Development Milestones 746

Appendix 758

List of Tables

List of Tables

Number of Products under Development for Multiple Sclerosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Tables

Number of Products under Development for Multiple Sclerosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Products under Development by Companies, H1 2018 (Contd..12), H1 2018

Products under Development by Companies, H1 2018 (Contd..13), H1 2018

Products under Development by Companies, H1 2018 (Contd..14), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..7), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..6), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..7), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Multiple Sclerosis – Pipeline by 4D Pharma PLC, H1 2018

Multiple Sclerosis – Pipeline by AB Science SA, H1 2018

Multiple Sclerosis – Pipeline by AbbVie Inc, H1 2018

Multiple Sclerosis – Pipeline by Abion Inc, H1 2018

Multiple Sclerosis – Pipeline by Abzena Plc, H1 2018

Multiple Sclerosis – Pipeline by Acorda Therapeutics Inc, H1 2018

Multiple Sclerosis – Pipeline by Actelion Pharmaceuticals Ltd, H1 2018

Multiple Sclerosis – Pipeline by Addex Therapeutics Ltd, H1 2018

Multiple Sclerosis – Pipeline by Adhaere Pharmaceuticals Inc, H1 2018

Multiple Sclerosis – Pipeline by Aegis Therapeutics LLC, H1 2018

Multiple Sclerosis – Pipeline by Affectis Pharmaceuticals AG, H1 2018

Multiple Sclerosis – Pipeline by AiCuris GmbH & Co KG, H1 2018

Multiple Sclerosis – Pipeline by Alpha Cancer Technologies Inc, H1 2018

Multiple Sclerosis – Pipeline by Amarna Therapeutics BV, H1 2018

Multiple Sclerosis – Pipeline by Anavex Life Sciences Corp, H1 2018

Multiple Sclerosis – Pipeline by Antisense Therapeutics Ltd, H1 2018

Multiple Sclerosis – Pipeline by Antoxis Ltd, H1 2018

Multiple Sclerosis – Pipeline by Aphios Corp, H1 2018

Multiple Sclerosis – Pipeline by Apitope International NV, H1 2018

Multiple Sclerosis – Pipeline by Arven Ilac, H1 2018

Multiple Sclerosis – Pipeline by AstraZeneca Plc, H1 2018

Multiple Sclerosis – Pipeline by Atara Biotherapeutics Inc, H1 2018

Multiple Sclerosis – Pipeline by Athersys Inc, H1 2018

Multiple Sclerosis – Pipeline by Atlantic Bio Sci LLC, H1 2018

Multiple Sclerosis – Pipeline by Axxam SpA, H1 2018

Multiple Sclerosis – Pipeline by Baliopharm AG, H1 2018

Multiple Sclerosis – Pipeline by BioApex sro, H1 2018

Multiple Sclerosis – Pipeline by Biocad, H1 2018

Multiple Sclerosis – Pipeline by Biocon Ltd, H1 2018

Multiple Sclerosis – Pipeline by Biogen Inc, H1 2018

Multiple Sclerosis – Pipeline by BioHealthonomics Inc, H1 2018

Multiple Sclerosis – Pipeline by Biond Biologics Ltd, H1 2018

Multiple Sclerosis – Pipeline by Bionovis SA, H1 2018

Multiple Sclerosis – Pipeline by Bionure Farma SL, H1 2018

Multiple Sclerosis – Pipeline by Biovista Inc, H1 2018

Multiple Sclerosis – Pipeline by Bolder Biotechnology Inc, H1 2018

Multiple Sclerosis – Pipeline by Boston Pharmaceuticals Inc, H1 2018

Multiple Sclerosis – Pipeline by BrainStorm Cell Therapeutics Inc, H1 2018

Multiple Sclerosis – Pipeline by Bristol-Myers Squibb Co, H1 2018

Multiple Sclerosis – Pipeline by BTB Pharma AB, H1 2018

Multiple Sclerosis – Pipeline by CASI Pharmaceuticals Inc, H1 2018

Multiple Sclerosis – Pipeline by Celgene Corp, H1 2018

Multiple Sclerosis – Pipeline by Cell2B Advanced Therapeutics SA, H1 2018

Multiple Sclerosis – Pipeline by Cellix Bio Pvt Ltd, H1 2018

Multiple Sclerosis – Pipeline by Cinnagen Co, H1 2018

Multiple Sclerosis – Pipeline by Cognosci Inc, H1 2018

Multiple Sclerosis – Pipeline by Coherus BioSciences Inc, H1 2018

Multiple Sclerosis – Pipeline by Commence Bio Inc, H1 2018

Multiple Sclerosis – Pipeline by Complement Pharma BV, H1 2018

Multiple Sclerosis – Pipeline by Compugen Ltd, H1 2018

Multiple Sclerosis – Pipeline by Cotinga Pharmaceuticals Inc, H1 2018

Multiple Sclerosis – Pipeline by CuraVac Inc, H1 2018

Multiple Sclerosis – Pipeline by Cyxone AB, H1 2018

Multiple Sclerosis – Pipeline by DanDrit Biotech A/S, H1 2018

Multiple Sclerosis – Pipeline by Denceptor Therapeutics Ltd, H1 2018

Multiple Sclerosis – Pipeline by Domain Therapeutics SA, H1 2018

Multiple Sclerosis – Pipeline by Eli Lilly and Co, H1 2018

Multiple Sclerosis – Pipeline by Endece LLC, H1 2018

Multiple Sclerosis – Pipeline by Evgen Pharma Plc, H1 2018

Multiple Sclerosis – Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Multiple Sclerosis – Pipeline by Fate Therapeutics Inc, H1 2018

Multiple Sclerosis – Pipeline by FPRT Bio Inc, H1 2018

Multiple Sclerosis – Pipeline by Gemac SA, H1 2018

Multiple Sclerosis – Pipeline by Genervon Biopharmaceuticals LLC, H1 2018

Multiple Sclerosis – Pipeline by GeNeuro SA, H1 2018

Multiple Sclerosis – Pipeline by Gilead Sciences Inc, H1 2018

Multiple Sclerosis – Pipeline by GlaxoSmithKline Plc, H1 2018

Multiple Sclerosis – Pipeline by Glialogix Inc, H1 2018

Multiple Sclerosis – Pipeline by Gliknik Inc, H1 2018

Multiple Sclerosis – Pipeline by GlyTag LLC, H1 2018

Multiple Sclerosis – Pipeline by Hansa Medical AB, H1 2018

Multiple Sclerosis – Pipeline by Harbor Therapeutics Inc, H1 2018

Multiple Sclerosis – Pipeline by Humanigen Inc, H1 2018

Multiple Sclerosis – Pipeline by ImCyse SA, H1 2018

Multiple Sclerosis – Pipeline by Immune Response BioPharma Inc, H1 2018

Multiple Sclerosis – Pipeline by Immungenetics AG, H1 2018

Multiple Sclerosis – Pipeline by Immunwork Inc, H1 2018

Multiple Sclerosis – Pipeline by Inception Sciences Inc, H1 2018

Multiple Sclerosis – Pipeline by Io Therapeutics Inc, H1 2018

Multiple Sclerosis – Pipeline by Istesso Ltd, H1 2018

Multiple Sclerosis – Pipeline by Johnson & Johnson, H1 2018

Multiple Sclerosis – Pipeline by Jyant Technologies Inc, H1 2018

Multiple Sclerosis – Pipeline by Kadimastem Ltd, H1 2018

Multiple Sclerosis – Pipeline by Kadmon Corp LLC, H1 2018

Multiple Sclerosis – Pipeline by KAHR medical Ltd, H1 2018

Multiple Sclerosis – Pipeline by Karo Pharma AB, H1 2018

Multiple Sclerosis – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Multiple Sclerosis – Pipeline by Lead Discovery Center GmbH, H1 2018

Multiple Sclerosis – Pipeline by LFB SA, H1 2018

Multiple Sclerosis – Pipeline by Lipocure Ltd, H1 2018

Multiple Sclerosis – Pipeline by Longevity Biotech Inc, H1 2018

Multiple Sclerosis – Pipeline by M3 Biotechnology Inc, H1 2018

Multiple Sclerosis – Pipeline by Mapi Pharma Ltd, H1 2018

Multiple Sclerosis – Pipeline by Maruho Co Ltd, H1 2018

Multiple Sclerosis – Pipeline by MedAnnex Ltd, H1 2018

Multiple Sclerosis – Pipeline by MedDay SA, H1 2018

Multiple Sclerosis – Pipeline by Merck KGaA, H1 2018

Multiple Sclerosis – Pipeline by Meta-IQ ApS, H1 2018

Multiple Sclerosis – Pipeline by Mitochon Pharmaceuticals Inc, H1 2018

Multiple Sclerosis – Pipeline by Mitotech SA, H1 2018

Multiple Sclerosis – Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018

Multiple Sclerosis – Pipeline by Mochida Pharmaceutical Co Ltd, H1 2018

Multiple Sclerosis – Pipeline by Momenta Pharmaceuticals Inc, H1 2018

Multiple Sclerosis – Pipeline by MorphoSys AG, H1 2018

Multiple Sclerosis – Pipeline by Mount Tam Biotechnologies Inc, H1 2018

Multiple Sclerosis – Pipeline by Neuren Pharmaceuticals Ltd, H1 2018

Multiple Sclerosis – Pipeline by Neurofx Inc, H1 2018

Multiple Sclerosis – Pipeline by Neuronax SAS, H1 2018

Multiple Sclerosis – Pipeline by New World Laboratories Inc, H1 2018

Multiple Sclerosis – Pipeline by Novartis AG, H1 2018

Multiple Sclerosis – Pipeline by Nuevolution AB, H1 2018

Multiple Sclerosis – Pipeline by Numab Innovation AG, H1 2018

Multiple Sclerosis – Pipeline by Ogeda SA, H1 2018

Multiple Sclerosis – Pipeline by Omeros Corp, H1 2018

Multiple Sclerosis – Pipeline by OncoImmune Inc, H1 2018

Multiple Sclerosis – Pipeline by Oryzon Genomics SA, H1 2018

Multiple Sclerosis – Pipeline by OSE Immunotherapeutics, H1 2018

Multiple Sclerosis – Pipeline by Pangen Biotech Inc., H1 2018

Multiple Sclerosis – Pipeline by Parvus Therapeutics Inc, H1 2018

Multiple Sclerosis – Pipeline by Pfizer Inc, H1 2018

Multiple Sclerosis – Pipeline by Principia Biopharma Inc, H1 2018

Multiple Sclerosis – Pipeline by ProNoxis AB, H1 2018

Multiple Sclerosis – Pipeline by Quimatryx SL, H1 2018

Multiple Sclerosis – Pipeline by ReceptoPharm Inc, H1 2018

Multiple Sclerosis – Pipeline by RedHill Biopharma Ltd, H1 2018

Multiple Sclerosis – Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2018

Multiple Sclerosis – Pipeline by Renovo Neural Inc, H1 2018

Multiple Sclerosis – Pipeline by Resverlogix Corp, H1 2018

Multiple Sclerosis – Pipeline by ReveraGen BioPharma Inc, H1 2018

Multiple Sclerosis – Pipeline by Rewind Therapeutics NV, H1 2018

Multiple Sclerosis – Pipeline by Rhizen Pharmaceuticals SA, H1 2018

Multiple Sclerosis – Pipeline by Rigel Pharmaceuticals Inc, H1 2018

Multiple Sclerosis – Pipeline by Rodos BioTarget GmbH, H1 2018

Multiple Sclerosis – Pipeline by Rubius Therapeutics Inc, H1 2018

Multiple Sclerosis – Pipeline by SanBio Inc, H1 2018

Multiple Sclerosis – Pipeline by Sanofi, H1 2018

Multiple Sclerosis – Pipeline by Sareum Holdings Plc, H1 2018

Multiple Sclerosis – Pipeline by Senju Pharmaceutical Co Ltd, H1 2018

Multiple Sclerosis – Pipeline by Sorrento Therapeutics Inc, H1 2018

Multiple Sclerosis – Pipeline by Synthon Holdings BV, H1 2018

Multiple Sclerosis – Pipeline by Teikoku Pharma USA Inc, H1 2018

Multiple Sclerosis – Pipeline by Tetra Discovery Partners LLC, H1 2018

Multiple Sclerosis – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018

Multiple Sclerosis – Pipeline by Tiziana Life Sciences Plc, H1 2018

Multiple Sclerosis – Pipeline by Toleranzia AB, H1 2018

Multiple Sclerosis – Pipeline by TolerogenixX GmbH, H1 2018

Multiple Sclerosis – Pipeline by Topas Therapeutics GmbH, H1 2018

Multiple Sclerosis – Pipeline by TxCell SA, H1 2018

Multiple Sclerosis – Pipeline by Vaccinex Inc, H1 2018

Multiple Sclerosis – Pipeline by Vakzine Projekt Management GmbH, H1 2018

Multiple Sclerosis – Pipeline by Vicore Pharma AB, H1 2018

Multiple Sclerosis – Pipeline by Vitality Biopharma Inc, H1 2018

Multiple Sclerosis – Pipeline by Yeda Research and Development Company Ltd, H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..1), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..2), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..3), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..4), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..5), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..6), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..7), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..8), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..9), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..10), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..11), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..12), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..13), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..14), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..15), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..16), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..17), H1 2018

Multiple Sclerosis – Dormant Projects, H1 2018 (Contd..18), H1 2018

Multiple Sclerosis – Discontinued Products, H1 2018

Multiple Sclerosis – Discontinued Products, H1 2018 (Contd..1), H1 2018

Multiple Sclerosis – Discontinued Products, H1 2018 (Contd..2), H1 2018

List of Figures

List of Figures

Number of Products under Development for Multiple Sclerosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Figures

Number of Products under Development for Multiple Sclerosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports